Simris

Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology

Retrieved on: 
Monday, March 6, 2023
ADC, Cyanobacteria, Therapy, CDMO, Microalgae, Quality of life, Partnership, Patient, Cancer, Trade, Senior, Fine chemical, Pharmaceutical industry, Simris

Stockholm, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Simris Alg AB (publ), a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, today announced a framework collaboration agreement with Lonza Ltd, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, to commercialize Simris’ ADC payload platform.

Key Points: 
  • With more than 210 novel ADC clinical trials started in 2022, the market for ADC medicines continues to develop in line with their recognition as effective, stable and reliable cancer therapeutics.
  • Under the terms of the agreement, Lonza will integrate Simris’ ADC payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.
  • In return, Simris will promote Lonza to customers as its exclusive contract drug and manufacturing organization (CDMO) partner for services using its ADC technology.
  • Julian Read, CEO at Simris Alg AB, commented, “We are delighted that Lonza shares our confidence in the potential of our ADC payload technology.

Simris Alg Management Update

Retrieved on: 
Monday, June 21, 2021
Simris, KTH Royal Institute of Technology, ALG, Fredrika, Microalgae, Academic disciplines

STOCKHOLM, June 21, 2021 /PRNewswire/ -- Simris Alg AB (publ) (FNSE: SIMRIS)("Simris" or "Company") advises that Fredrika Gullfot has tendered her resignation as CEO of the Company.

Key Points: 
  • STOCKHOLM, June 21, 2021 /PRNewswire/ -- Simris Alg AB (publ) (FNSE: SIMRIS)("Simris" or "Company") advises that Fredrika Gullfot has tendered her resignation as CEO of the Company.
  • Fredrika Gullfot, who holds a PhD in engineering in biotechnology from KTH Royal Institute of Technology in Stockholm, founded Simris Alg in 2011 and is globally recognized as a pioneer in microalgae technology.
  • Fredrika Gullfot said: "I have founded and lead Simris Alg for over a decade, and am immensely proud of what we have built together.
  • Chairman Steven Schapera stated: "Fredrika has positioned Simris as a best-in-class innovator, at the forefront of the global marine microalgae space.

Simris Alg signs agreement on research collaboration

Retrieved on: 
Thursday, May 6, 2021
Aquatic ecology, Biological oceanography, Microalgae, Planktology, Simris, Branches of biology, Algae, Biology, Academic disciplines

b"STOCKHOLM, May 6, 2021 /PRNewswire/ -- Simris Alg AB (publ) has entered a five-year agreement with Anhalt University of Applied Sciences in Germany (AUAS) for the development of novel biologically active substances from microalgae for advanced skincare.

Key Points: 
  • b"STOCKHOLM, May 6, 2021 /PRNewswire/ -- Simris Alg AB (publ) has entered a five-year agreement with Anhalt University of Applied Sciences in Germany (AUAS) for the development of novel biologically active substances from microalgae for advanced skincare.
  • The research on microalgae at AUAS is led by Prof. Dr. Claudia Grewe, who has over ten years of industry experience from leadership positions in research, development and production.
  • The collaboration increases Simris Alg's R&D capacity and aims to accelerate product development within the company's Simris Biomimetics business area.\nSimris Biomimetics, together with Simris Novel Foods and the consumer brand SIMRIS, is one of Simris Alg's three business verticals.
  • Simris Biomimeticsis devoted to research, development and commercialisation of substances and extracts from microalgae for applications in advanced skincare and bio-based pharmaceuticals.

Simris Rights Issue Was Oversubscribed

Retrieved on: 
Friday, July 10, 2020
Simris

STOCKHOLM, July 10, 2020 /PRNewswire/ -- Simris (FNSE: SIMRIS) has concluded its rights issue of units which was announced on 12 June 2020.

Key Points: 
  • STOCKHOLM, July 10, 2020 /PRNewswire/ -- Simris (FNSE: SIMRIS) has concluded its rights issue of units which was announced on 12 June 2020.
  • Simris receives circa SEK 29.1 million before transaction costs from the rights issue, of which circa SEK 2.2 million will be funded through offset of debt.
  • Simris receives circa SEK 29.1 million before transaction costs from the rights issue, of which circa SEK2.2million will be funded through offset of debt.
  • Simris shares are traded on the Nasdaq First North Growth Market with ticker SIMRIS and ISIN SE0008091664.

Simris CEO and Founder Transfers Unit Rights to Beauty Industry Veteran in Ongoing Rights Issue

Retrieved on: 
Tuesday, July 7, 2020
Simris, SEK, Fredrika

STOCKHOLM, July 7, 2020 /PRNewswire/ -- Simris (FNSE: SIMRIS), a Swedish agribusiness growing algae to replace unstainable marine ingredients, is currently raising capital through a 29.1 MSEK rights issue.

Key Points: 
  • STOCKHOLM, July 7, 2020 /PRNewswire/ -- Simris (FNSE: SIMRIS), a Swedish agribusiness growing algae to replace unstainable marine ingredients, is currently raising capital through a 29.1 MSEK rights issue.
  • Founder and CEO Fredrika Gullfot has transferred unit rights to an investment entity associated withbeauty industry veteran Steven Schapera, who participates in the rights issue with a subscription of 480 000 units corresponding to circa 1.3 MSEK.
  • Founder and CEO Fredrika Gullfot is the second largest shareholder in Simris with 4.7 percent of the stock and 5.8percent of the voting rights.
  • Simris currently seeks to raise SEK 29.1 million through a rights issue of units at 0.90 SEK per share.